Agenus’ (AGEN) Neutral Rating Reaffirmed at HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $2.05 on Wednesday. Agenus has a fifty-two week low of $1.93 and a fifty-two week high of $19.69. The stock’s 50-day simple moving average is $3.24 and its 200-day simple moving average is $3.85. The firm has a market capitalization of $48.09 million, a PE ratio of -0.18 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million. On average, sell-side analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several hedge funds have recently bought and sold shares of AGEN. B. Riley Financial Inc. acquired a new stake in shares of Agenus in the fourth quarter worth approximately $2,074,000. Geode Capital Management LLC grew its position in shares of Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after buying an additional 32,016 shares in the last quarter. State Street Corp grew its holdings in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after acquiring an additional 9,731 shares in the last quarter. Gilead Sciences Inc. bought a new stake in Agenus in the fourth quarter valued at about $635,000. Finally, Northern Trust Corp raised its position in shares of Agenus by 14.8% during the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company’s stock valued at $572,000 after acquiring an additional 26,870 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.